Resistance to decitabine and 5-azacytidine emerges from adaptive responses of the pyrimidine metabolism network
X. Gu, R. Tohme, B. Tomlinson, M. Hasipek, L. Durkin, C. Schuerger, A. M. Zidan, T. Radivoyevitch, C. Hong, H. Carraway, B. Hamilton, R. Sobecks, B. K. Jha, E. D. Hsi, J. Maciejewski, Y. Saunthararajah
This paper identifies adaptive metabolic responses in pyrimidine metabolism as a mechanism of resistance to decitabine and 5-azacytidine, and shows that alternating these drugs with metabolic inhibitors can extend DNMT1 depletion and delay leukemia relapse.
bioRxiv · Feb 20, 2020Cancer Biology